← Back to Search

Diagnostic Test

Biospecimen Collection for Coronavirus Disease (END CoV-2 Trial)

N/A
Waitlist Available
Led By Kathleen M Schmeler
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

END CoV-2 Trial Summary

This trial looks at a new way to test for SARS-CoV-2, the virus that causes COVID-19. The hope is that this will improve testing for the disease.

Eligible Conditions
  • Coronavirus Disease (COVID-19)

END CoV-2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Concordance of the novel point-of-care diagnostic test
Negative predictive value (NPV) of the novel point-of-care diagnostic test
Positive predictive value (PPV) of the novel point-of-care diagnostic test
+2 more
Secondary outcome measures
Disease progression
Viral load metrics

END CoV-2 Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (biospecimen collection)Experimental Treatment2 Interventions
Participants undergo collection of nasopharyngeal (back of the nose) samples by a medical provider and self-collection of oral, saliva, and nasal samples.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 2
~1720

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,987 Previous Clinical Trials
1,797,978 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,717 Previous Clinical Trials
40,953,099 Total Patients Enrolled
1 Trials studying Coronavirus Disease
189 Patients Enrolled for Coronavirus Disease
William Marsh Rice UniversityOTHER
45 Previous Clinical Trials
27,688 Total Patients Enrolled
~51 spots leftby Jun 2025